Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids
出版年份 2014 全文链接
标题
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids
作者
关键词
Cannabinoid, Cannabidiol, Experimental autoimmune encephalomyelitis, Multiple sclerosis, Neuroprotection, Δ9-tetrahydrocannabinol
出版物
Journal of Neuroimmune Pharmacology
Volume 10, Issue 2, Pages 281-292
出版商
Springer Nature
发表日期
2014-12-23
DOI
10.1007/s11481-014-9575-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
- (2015) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
- (2014) Fabio Arturo Iannotti et al. ACS Chemical Neuroscience
- A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis
- (2014) Gloria Hernández-Torres et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelinationin vivo
- (2014) Ana Bernal-Chico et al. GLIA
- Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology
- (2014) V. Yadav et al. NEUROLOGY
- Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis
- (2014) Alessandra Musella et al. NEUROPHARMACOLOGY
- Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se
- (2014) Andrew J. Hill et al. NEUROSCIENCE LETTERS
- Association between a Genetic Variant of Type-1 Cannabinoid Receptor and Inflammatory Neurodegeneration in Multiple Sclerosis
- (2014) Silvia Rossi et al. PLoS One
- Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely
- (2014) David Baker et al. Multiple Sclerosis and Related Disorders
- Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters
- (2014) Michelle Sexton et al. INFLAMMOPHARMACOLOGY
- Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis
- (2013) Sarah Al-Izki et al. BRAIN
- Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis
- (2013) Damineh Morsali et al. BRAIN
- Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists
- (2013) Gareth Pryce et al. FASEB JOURNAL
- Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
- (2013) John Zajicek et al. LANCET NEUROLOGY
- Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- (2013) M. Mecha et al. NEUROBIOLOGY OF DISEASE
- Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors
- (2013) Francisco Espejo-Porras et al. NEUROPHARMACOLOGY
- Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis
- (2013) R. Ribeiro et al. NEUROSCIENCE
- Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
- (2013) Sharmilee Gnanapavan et al. PLoS One
- Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis
- (2013) Sofia Sisay et al. PLoS One
- Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
- (2012) J. Corey-Bloom et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
- (2012) R. M. Langford et al. JOURNAL OF NEUROLOGY
- Δ9-tetrahydrocannabinol (Δ9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease
- (2012) C. B. Carroll et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
- (2012) Eva de Lago et al. NEUROPHARMACOLOGY
- Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress
- (2012) M Mecha et al. Cell Death & Disease
- The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
- (2012) David Baker et al. Multiple Sclerosis and Related Disorders
- Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis
- (2011) Silvia Rossi et al. BRAIN BEHAVIOR AND IMMUNITY
- Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
- (2011) Ewa Kozela et al. BRITISH JOURNAL OF PHARMACOLOGY
- Heterogeneity in the composition of marijuana seized in California
- (2011) James Richard Burgdorf et al. DRUG AND ALCOHOL DEPENDENCE
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
- (2011) A. Novotna et al. EUROPEAN JOURNAL OF NEUROLOGY
- CB1 receptor antagonism/inverse agonism increases motor system excitability in humans
- (2011) A. Oliviero et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis
- (2011) David Baker et al. JOURNAL OF NEUROIMMUNOLOGY
- Critical appraisal of animal models of multiple sclerosis
- (2011) David Baker et al. Multiple Sclerosis Journal
- Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse
- (2011) Sarah Al-Izki et al. Multiple Sclerosis and Related Disorders
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
- (2010) Martin Gunnarsson et al. ANNALS OF NEUROLOGY
- Evidence for a two-stage disability progression in multiple sclerosis
- (2010) E. Leray et al. BRAIN
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2010) Raju Kapoor et al. LANCET NEUROLOGY
- The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis
- (2010) Silvia Rossi et al. Multiple Sclerosis Journal
- Neuroprotection without Immunomodulation Is Not Sufficient to Reduce First Relapse Severity in Experimental Autoimmune Encephalomyelitis
- (2010) Henrik Hasseldam et al. NEUROIMMUNOMODULATION
- Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+ Levels
- (2009) D. Ryan et al. JOURNAL OF NEUROSCIENCE
- A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells
- (2008) Fernando Correa et al. BIOCHEMICAL PHARMACOLOGY
- Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinol
- (2008) Robert E. Vann et al. DRUG AND ALCOHOL DEPENDENCE
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis
- (2008) Michael Webb et al. NEUROSCIENCE LETTERS
- Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors
- (2007) G Pryce et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- (2007) A Thomas et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis
- (2007) J. Ludovic Croxford et al. JOURNAL OF NEUROIMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started